Clinical Trials
5
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (100.0%)PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies
Phase 1
- Conditions
- Solid Tumor, AdultAdvanced Cancer
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03030001
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer
Phase 1
- Conditions
- Precision Cell ImmunotherapyChemotherapyAdvanced Lung Cancer
- Interventions
- Drug: ChemotherapyBiological: Precision Cells
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873416
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor
Phase 1
- Conditions
- CAR-T CellsAdvanced MalignanciesPD-1 Antibody
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02873390
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer
Phase 1
- Conditions
- ChemotherapyPrecision Cell ImmunotherapyAdvanced Gastric Cancer
- Interventions
- Drug: ChemotherapyBiological: Precision Cell Immunotherapy
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873520
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Phase 1
- Conditions
- Advanced Liver CancerTranscatheter Arterial ChemoembolizationPrecision Cell Immunotherapy
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Ningbo Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02873442
- Locations
- 🇨🇳
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
News
No news found